First, the Hims advertisement violates your Guidelines for Health Related Product Advertising. According to the Guidelines, [p]rescription drug advertising must adequately reflect FDA guidelines for prescription drug commercials. Advertisements must also be accurate and not misleading, contain all material facts, communicate clearly that the product is available by prescription only, and instruct viewers to consult their physicians regarding the product. They must also disclose the most significant risks that appear in the labeling and contain a brief summary of all necessary information related to side effects and contraindications. Hims advertisement does not comply with any of these requirements, despite being specifically intended to market Hims prescription drug products including compounded, unapproved semaglutide
Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL
Our approach remains disciplined and value-focused, positioning this as a strong mid-to-long-term opportunity with meaningful upside. Srinivas Sadu, Executive Chairman, Gland Pharma | Q4 FY26 The neat thing about this bet is that these companies dont care who wins the Indian launch war
This ongoing inflammatory fire drives many of the debilitating, systemic symptoms patients experience months or even years after the initial acute infection has seemingly cleared
Albiglutide is administered once weekly by subcutaneous injection and is thought to be absorbed through the lymphatic circulation [23]
)
